drugset / Trial / NCT01272414
Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction
RandomizedParallel-groupSingle-blindTreatment
Summary
Currently there are few therapeutic options for the treatment of lid retraction secondary to thyroid orbitopathy (TO) during the active stages of the disease. BoTox injection is capable of creating a ptosis, that in the setting of TO can return the upper lid to a more physiologic position, thus improving cosmesis, corneal lubrication and potentially quiescent stage lid position. This investigation aims to examine the properties of this relationship.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-01
- Completion
- 2012-02
Outcome
Outcome not reported
Stopped (Business): “lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 2 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 4 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 6 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 8 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 10 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 12 iu | — |